What's Happening?
Hong Kong-based biopharma company Akeso has received clinical trial clearance in China for its next-generation antibody-drug conjugate (ADC), AK157D1, which targets B7-H3. This clearance paves the way for a Phase I study in patients with advanced solid
tumors. AK157D1 is the third of Akeso’s next-generation ADC candidates to enter clinical development, following TROP2/Nectin-4-targeting AK146D1 and HER3-directed AK138D1. Akeso plans to test AK157D1 in combination with its bispecific antibodies, ivonescimab and cadonilimab, as part of its 'IO2.0 + ADC2.0' strategy. B7-H3 is an immune checkpoint protein found in various solid tumors, including non-small cell lung cancer, prostate, colorectal, and breast cancers, making it a prime target for antibody-based therapies. AK157D1 uses a humanized IgG1 antibody linked to Dxd, a topoisomerase I inhibitor, to deliver the treatment directly to cancer cells. Preclinical testing showed anti-tumor activity and a favorable safety profile, potentially addressing toxicity issues associated with existing ADCs. Separately, CStone Pharmaceuticals also received approval for an investigational new drug application in China for CS5007, an EGFR/HER3 bispecific ADC, with a global Phase I study already underway in Australia.
Why It's Important?
While the immediate clearances are in China, the advancements in next-generation Antibody-Drug Conjugates (ADCs) by companies like Akeso and CStone have significant implications for the U.S. pharmaceutical industry and cancer treatment. The development of ADCs targeting proteins like B7-H3, which are prevalent in various solid tumors, represents a promising avenue for more precise and effective cancer therapies. The U.S. market is a major hub for oncology research and development, and successful clinical trials in other regions often precede or run in parallel with U.S. trials. The potential for these ADCs to address toxicity issues seen with current treatments, such as hematological toxicities and interstitial lung disease, could lead to safer and more tolerable options for U.S. patients. Furthermore, the 'IO2.0 + ADC2.0' strategy, combining ADCs with bispecific antibodies, signifies an evolving approach to cancer immunotherapy that could influence future drug development and treatment protocols in the U.S., offering new hope for patients with advanced solid tumors who have limited treatment options.
What's Next?
Akeso will proceed with its Phase I study of AK157D1 in China, evaluating its safety and efficacy in patients with advanced solid tumors. The company's plans to test AK157D1 in combination with its bispecific antibodies suggest a future direction towards multi-modal cancer therapies. The preclinical findings, which indicated a favorable safety profile and anti-tumor activity, will be further scrutinized in human trials. For CStone Pharmaceuticals, the approval of CS5007 in China will allow for parallel development with its ongoing global Phase I study in Australia, accelerating the overall development timeline. The aim is to address resistance mechanisms that can emerge after EGFR-targeted treatments. The outcomes of these early-phase trials will be crucial in determining the potential for these next-generation ADCs to enter later-stage clinical development and eventually seek regulatory approval in markets like the U.S. The industry will closely watch for data on safety, tolerability, and early signs of anti-tumor activity to assess their broader therapeutic potential.
Beyond the Headlines
The emergence of next-generation ADCs like AK157D1 and CS5007 signifies a deeper understanding of cancer biology and a more sophisticated approach to drug delivery. By using cancer cells' own surface proteins as 'Trojan horses,' these therapies aim to deliver potent cytotoxic agents directly to tumors while minimizing harm to healthy tissues. This precision medicine approach could revolutionize cancer treatment by offering highly targeted therapies that are both more effective and less toxic than conventional chemotherapy. The focus on B7-H3 and EGFR/HER3 targets reflects the ongoing effort to identify and exploit unique vulnerabilities of cancer cells. If successful, these innovations could lead to a paradigm shift in how various solid tumors, including those resistant to current treatments, are managed. The ethical implications of such highly targeted therapies also include ensuring equitable access and affordability, as these advanced treatments often come with high costs, posing challenges for healthcare systems globally, including in the U.S.
